The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor.
暂无分享,去创建一个
Christine Brideau | Yves Ducharme | Marc Ouellet | C. Brideau | M. Ouellet | R. Friesen | Y. Gareau | F. Massé | Y. Ducharme | M. Blouin | E. Grimm | H. Juteau | M. Salem | A. Châteauneuf | Sébastien Laliberté | B. Mackay | A. Styhler | Yves Gareau | Marc Blouin | Anne Châteauneuf | Erich L. Grimm | Hélène Juteau | Sébastien Laliberté | Bruce MacKay | Frédéric Massé | Myriam Salem | Angela Styhler | Richard W. Friesen | Erich L Grimm | H. Jûteau | A. Châteauneuf
[1] W. Storms. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction , 2007, Expert opinion on pharmacotherapy.
[2] D. Riendeau,et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. , 1992, Canadian journal of physiology and pharmacology.
[3] C. Brideau,et al. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. , 1993, The Journal of pharmacology and experimental therapeutics.
[4] P. Sterk,et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.
[5] R. Young,et al. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. , 2003, Journal of medicinal chemistry.
[6] W. Berger,et al. Zileuton: clinical implications of 5‐Lipoxygenase inhibition in severe airway disease , 2007, International journal of clinical practice.
[7] J. Masferrer,et al. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. , 2009, European journal of pharmacology.
[8] P. Drakatos,et al. Targeting leukotrienes for the treatment of COPD? , 2009, Inflammation & allergy drug targets.
[9] O. Werz,et al. 5-Lipoxygenase: regulation of expression and enzyme activity. , 2007, Trends in biochemical sciences.
[10] M. Bäck. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. , 2009, Current pharmaceutical design.
[11] Oliver Werz,et al. Therapeutic options for 5-lipoxygenase inhibitors. , 2006, Pharmacology & therapeutics.
[12] M. Balazy,et al. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. , 2004, Current drug targets. Inflammation and allergy.
[13] J. Falgueyret,et al. Substituted coumarins as potent 5-lipoxygenase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[14] Jilly F. Evans,et al. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. , 2008, Trends in pharmacological sciences.
[15] Reynold A Panettieri,et al. Asthma , 1894, Annals of Internal Medicine.
[16] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.